SAB BIO reports Phase 1 data showing C-peptide preservation signals

March 10, 2026 7:31 AM

SAB Biotherapeutics Inc. (NASDAQ: SABS) announced additional Phase 1 data for its drug candidate SAB-142 in adult patients with established ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found